Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis

Primary nonresponse to infliximab in patients with ulcerative colitis (UC) is common. However, there are currently no effective biomarkers for this prediction. This study aimed to identify potential predictors for precision anti-tumor necrosis factor-alpha treatment in patients with UC. Four GPL570...

Full description

Bibliographic Details
Main Authors: Jixiang Zhang, Xiaohan Wu, Shuchun Wei, Chuan Liu, Xiaoli Wang, Weiguo Dong
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Autoimmunity
Subjects:
Online Access:http://dx.doi.org/10.1080/08916934.2022.2103803
_version_ 1797684583610712064
author Jixiang Zhang
Xiaohan Wu
Shuchun Wei
Chuan Liu
Xiaoli Wang
Weiguo Dong
author_facet Jixiang Zhang
Xiaohan Wu
Shuchun Wei
Chuan Liu
Xiaoli Wang
Weiguo Dong
author_sort Jixiang Zhang
collection DOAJ
description Primary nonresponse to infliximab in patients with ulcerative colitis (UC) is common. However, there are currently no effective biomarkers for this prediction. This study aimed to identify potential predictors for precision anti-tumor necrosis factor-alpha treatment in patients with UC. Four GPL570 datasets (GSE14580, GSE12251, GSE23597, and GSE16879) were included in this study. Sixty-nine differentially expressed genes (DEGs) were identified, while 67 were up-regulated and two were down-regulated by comparing the gene expression in response samples with the nonresponse samples. Gene Ontology analysis showed that DEGs were mostly enriched in neutrophil-mediated immunity, neutrophil activation, neutrophil activation involved in the immune response, neutrophil degranulation, and leukocyte migration. Kyoto Encyclopaedia of Genes and Genomes analysis indicated that these DEGs were mostly enriched in cytokine-cytokine receptor interactions and interleukin (IL)-17 signalling pathways. After protein-protein interaction network analysis, verification by test set, and confirmation of clinical UC samples, S100 calcium-binding protein A8 (S100A8), S100A9, triggering receptor expressed on myeloid cells 1 (TREM1), toll-like receptor 2 (TLR2), IL1B, and formyl peptide receptor 1 (FPR1) were identified as the hub genes. We found that the immune cell composition in the intestinal tissues of UC patients with primary nonresponse included naïve CD4+ T cells, memory resting CD4+ T cells, resting natural killer cells, resting dendritic cells, activating dendritic cells, eosinophils, and neutrophils. Among these, neutrophils showed the most significant differences. In addition, all six potential predictors were significantly associated with the neutrophil count. Our study identified six potential biomarkers, namely S100A8, S100A9, TREM1, TLR2, IL1B, and FPR1, and one type of immune cell, neutrophils, between UC patients with response and primary nonresponse to infliximab. We speculated that changes in the expression of these six potential biomarkers combined with changes in the activity or local quantity of neutrophils might help predict primary nonresponse to infliximab in patients with UC.
first_indexed 2024-03-12T00:31:51Z
format Article
id doaj.art-0e67bb00e58f4ece96f28bc8b333bda1
institution Directory Open Access Journal
issn 0891-6934
1607-842X
language English
last_indexed 2024-03-12T00:31:51Z
publishDate 2022-11-01
publisher Taylor & Francis Group
record_format Article
series Autoimmunity
spelling doaj.art-0e67bb00e58f4ece96f28bc8b333bda12023-09-15T10:12:25ZengTaylor & Francis GroupAutoimmunity0891-69341607-842X2022-11-0155853854810.1080/08916934.2022.21038032103803Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitisJixiang Zhang0Xiaohan Wu1Shuchun Wei2Chuan Liu3Xiaoli Wang4Weiguo Dong5Department of Gastroenterology, Renmin Hospital of Wuhan UniversityDepartment of Gastroenterology, Renmin Hospital of Wuhan UniversityDepartment of Gastroenterology, Renmin Hospital of Wuhan UniversityDepartment of Gastroenterology, Renmin Hospital of Wuhan UniversityDepartment of Plastic Surgery, Renmin Hospital of Wuhan UniversityDepartment of Gastroenterology, Renmin Hospital of Wuhan UniversityPrimary nonresponse to infliximab in patients with ulcerative colitis (UC) is common. However, there are currently no effective biomarkers for this prediction. This study aimed to identify potential predictors for precision anti-tumor necrosis factor-alpha treatment in patients with UC. Four GPL570 datasets (GSE14580, GSE12251, GSE23597, and GSE16879) were included in this study. Sixty-nine differentially expressed genes (DEGs) were identified, while 67 were up-regulated and two were down-regulated by comparing the gene expression in response samples with the nonresponse samples. Gene Ontology analysis showed that DEGs were mostly enriched in neutrophil-mediated immunity, neutrophil activation, neutrophil activation involved in the immune response, neutrophil degranulation, and leukocyte migration. Kyoto Encyclopaedia of Genes and Genomes analysis indicated that these DEGs were mostly enriched in cytokine-cytokine receptor interactions and interleukin (IL)-17 signalling pathways. After protein-protein interaction network analysis, verification by test set, and confirmation of clinical UC samples, S100 calcium-binding protein A8 (S100A8), S100A9, triggering receptor expressed on myeloid cells 1 (TREM1), toll-like receptor 2 (TLR2), IL1B, and formyl peptide receptor 1 (FPR1) were identified as the hub genes. We found that the immune cell composition in the intestinal tissues of UC patients with primary nonresponse included naïve CD4+ T cells, memory resting CD4+ T cells, resting natural killer cells, resting dendritic cells, activating dendritic cells, eosinophils, and neutrophils. Among these, neutrophils showed the most significant differences. In addition, all six potential predictors were significantly associated with the neutrophil count. Our study identified six potential biomarkers, namely S100A8, S100A9, TREM1, TLR2, IL1B, and FPR1, and one type of immune cell, neutrophils, between UC patients with response and primary nonresponse to infliximab. We speculated that changes in the expression of these six potential biomarkers combined with changes in the activity or local quantity of neutrophils might help predict primary nonresponse to infliximab in patients with UC.http://dx.doi.org/10.1080/08916934.2022.2103803primary nonresponseinfliximabulcerative colitispredictneutrophil
spellingShingle Jixiang Zhang
Xiaohan Wu
Shuchun Wei
Chuan Liu
Xiaoli Wang
Weiguo Dong
Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis
Autoimmunity
primary nonresponse
infliximab
ulcerative colitis
predict
neutrophil
title Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis
title_full Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis
title_fullStr Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis
title_full_unstemmed Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis
title_short Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis
title_sort identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis
topic primary nonresponse
infliximab
ulcerative colitis
predict
neutrophil
url http://dx.doi.org/10.1080/08916934.2022.2103803
work_keys_str_mv AT jixiangzhang identifiedpotentialbiomarkersmaypredictprimarynonresponsetoinfliximabinpatientswithulcerativecolitis
AT xiaohanwu identifiedpotentialbiomarkersmaypredictprimarynonresponsetoinfliximabinpatientswithulcerativecolitis
AT shuchunwei identifiedpotentialbiomarkersmaypredictprimarynonresponsetoinfliximabinpatientswithulcerativecolitis
AT chuanliu identifiedpotentialbiomarkersmaypredictprimarynonresponsetoinfliximabinpatientswithulcerativecolitis
AT xiaoliwang identifiedpotentialbiomarkersmaypredictprimarynonresponsetoinfliximabinpatientswithulcerativecolitis
AT weiguodong identifiedpotentialbiomarkersmaypredictprimarynonresponsetoinfliximabinpatientswithulcerativecolitis